Insider Transactions in Q4 2021 at Xilio Therapeutics, Inc. (XLO)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.44%
|
$225,000
$9.9 P/Share
|
|
Dec 09
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,011
+0.14%
|
$36,099
$9.84 P/Share
|
|
Dec 08
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
13,458
+0.48%
|
$121,122
$9.62 P/Share
|
|
Oct 26
2021
|
Sv7 Impact Medicine Fund LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,301,132
+34.43%
|
-
|
|
Oct 26
2021
|
Sv7 Impact Medicine Fund LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,301,132
+34.43%
|
-
|
|
Oct 26
2021
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
1,881,355
+36.48%
|
-
|
|
Oct 26
2021
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
775,000
+25.3%
|
$12,400,000
$16.0 P/Share
|
|
Oct 26
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,512,944
+50.0%
|
-
|
|
Oct 26
2021
|
Fil LTD |
BUY
Conversion of derivative security
|
Indirect |
218,705
+50.0%
|
-
|
|
Oct 26
2021
|
Alexandria Venture Investments, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
166,423
+50.0%
|
-
|
|
Oct 26
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
187,500
+20.3%
|
$3,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,545,529
+41.03%
|
-
|
|
Oct 26
2021
|
Bay City Capital LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
312,500
+21.67%
|
$5,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
Bay City Capital LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
816,990
+32.81%
|
-
|
|
Oct 26
2021
|
K Ga A Merck > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
680,825
+39.0%
|
-
|
|
Oct 26
2021
|
River Vest Venture Fund Iv, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+14.78%
|
$4,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
River Vest Venture Fund Iv, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,191,444
+36.59%
|
-
|
|
Oct 26
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,475,121
+50.0%
|
-
|
|
Oct 26
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+28.47%
|
$8,000,000
$16.0 P/Share
|
|
Oct 26
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
907,766
+50.0%
|
-
|